The daily use of a pill with antiretrovirals (TDF/FTC) has been proven to be effective in preventing HIV infection. However, compliance with a daily regimen is a challenge for most people.
Strategic Vision: Accelerate the decline in incidences of HIV infection by ensuring development and use of impactful prevention and treatment interventions.
The investment is to protect against incident infection: to ensure the development and efficient use of prevention interventions to maximize the reduction of new infections. The foundation strategy is to Develop effective long-acting prevention interventions to further decrease incidence.
Intarcia is a US based biotech company that has developed a pump device that is capable of delivering Type 2 Diabetes medication over a prolonged period of time (6 months – 1 year)
Foundation Focus: By investing in Intarcia the foundation will have access to this technology. Our population of interest is young women in sub-Saharan Africa who have a high burden of HIV infections.
$50 million. Series EE
Date: December 2016
Co-Investors: Fidelity, Baupost, Venrock and others.
Associated funding of up to $90 million to further support the development of this technology